Abstract:<h3 class="Heading">Background</h3><p class="Para">The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on <em class="EmphasisTypeItalic">S</em> values, which are pre-computed for reference anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate the potential value of image-based BM localization.</p><p class="Para">This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177 whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of bone lesions (MC2). Results were compared with those from <em class="EmphasisTypeItalic">S</em> values (SMIRD). BM absorbed doses were correlated with the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.</p><h3 class="Heading">Results</h3><p class="Para">Median BM absorbed doses were 130, 37, and 11 mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: <em class="EmphasisTypeItalic">r</em> = − 0.63, <em class="EmphasisTypeItalic">p</em> = 0.04; MC2: r = − 0.71, <em class="EmphasisTypeItalic">p</em> = 0.01; SMIRD: <em class="EmphasisTypeItalic">r</em> = − 0.62, <em class="EmphasisTypeItalic">p</em> = 0.04). For both investigated patients, BM localization via Tc-99m-anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.</p><h3 class="Heading">Conclusion</h3><p class="Para">Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and future studies are recommended to support an improvement for the prediction of hematoxicities.</p>

Internal Dosimetry Assessment of Beta, Beta/Auger, and Alpha Decaying Radionuclidesin Targeted Radionuclide Therapy for Prostate Cancer: A Simulation Study

Evaluation Of The Dosimetric Impact Of Interfractional Anatomical Variations On Prostate Proton Therapy Using Daily In-Room Ct Images

β-delayed multiple-particle emitters minibeam radiation therapy: first dosimetric evaluation with Monte Carlo simulations

Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer

Monte Carlo Simulation of Liver Dosimetry with Yttrium-90 Radionuclide Using Gate: 3D Phantom

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu

Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters

In vitro and preclinical systematic dose-effect studies of Auger electron- and beta particle-emitting radionuclides and external beam radiation for cancer treatment

Fast full patient and radioisotope Monte Carlo simulations of targeted radionuclide therapy: introducing egs_mird

SU-GG-T-347: Methods to Calculate Organ Doses Due to Scattered Radiation From External Beam Radiation Treatment Using Various Patient Phantoms and Monte Carlo Simulations

Calculations of beta radiation doses from multiwell Phosphorus-32 and Yttrium-90 applicators designed to be used in the treatment of superficial skin tumors: comparison of Monte Carlo and analytical methods

Assessment of individual organ doses in a realistic human phantom from neutron and gamma stimulated spectroscopy of the breast and liver

Physics and small‐scale dosimetry of α ‐emitters for targeted radionuclide therapy: The case of 211At

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs

Modeling the effect of daughter migration on dosimetry estimates for unlabeled actinium‐225

Microdosimetric quantities of an accelerator-based neutron source used for boron neutron capture therapy measured using a gas-filled proportional counter

Dose and DNA damage modelling of diffusing alpha-emitters radiation therapy using Geant4

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT

Calculation of Organ Dose Distribution (in-field and Out-of-field) in Breast Cancer Radiotherapy on RANDO Phantom Using GEANT4 Application for Tomographic Emission (Gate) Monte Carlo Simulation

Dose-rate effects and tumor control probability in177Lu-based targeted radionuclide therapy: a theoretical analysis

MO‐E‐T‐617‐07: Simulation of Organ Specific Secondary Neutron Dose in Proton Beam Treatments